$MBRXJul 6, 2026, 8:33 AM ETAI processed
MBRX: CEO flags positive preliminary Phase 2/3 MIRACLE Annamycin efficacy in first 45 patients
AI Summary
Moleculin CEO Walter Klemp presented positive preliminary unblinded efficacy trends from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) in relapsed/refractory AML and discussed commercial potential and market research. These are early, unblinded results from a small sample (n=45) that have not reached statistical significance and remain subject to further review; the company says prior Phase 1B/2 work and FDA input have helped de-risk the program but will require significant additional financing to complete development.
Positives
- Early unblinded efficacy trends reported positive across both Annamycin treatment arms in first 45 patients
- MIRACLE is a pivotal, adaptive Phase 2/3 randomized, double-blind, placebo-controlled trial (potential registration path)
- Company cites prior Phase 1B/2 success and FDA input as evidence of a de-risked development pathway
Negatives
- Interim dataset is small (n=45) and results have not achieved statistical significance
- Results were unblinded and explicitly subject to review and may not predict final trial outcome
- Company will require significant additional financing and has no commitments in place